Medical Management of Opioid-Induced Constipation
Publication Date: January 1, 2019
Last Updated: December 15, 2022
Treatment
Summary of Recommendations of AGA Clinical Guidelines for the Medical Management of OIC
Traditional laxatives
In patients with OIC, AGA recommends use of laxatives as first-line agents. ( Moderate , Strong )
612
Peripherally-acting µ-opioid receptor antagonists
In patients with laxative refractory OIC, AGA recommends naldemedine over no treatment. ( High , Strong )
612
In patients with laxative refractory OIC, AGA recommends naloxegol over no treatment. ( Moderate , Strong )
612
In patients with laxative refractory OIC, AGA suggests methylnaltrexone over no treatment. ( Low , Conditional (weak) )
612
Intestinal secretagogues
In patients with OIC, AGA makes no recommendation for the use of lubiprostone. ( Evidence Gap , No recommendation )
612
Selective 5-HT agonists
In patients with OIC, AGA makes no recommendation for the use of prucalopride. ( Evidence Gap , No recommendation )
612
Recommendation Grading
Overview
Title
Medical Management of Opioid-Induced Constipation
Authoring Organization
American Gastroenterological Association
Publication Month/Year
January 1, 2019
Last Updated Month/Year
October 3, 2024
Supplemental Implementation Tools
Document Type
Guideline
External Publication Status
Published
Country of Publication
US
Document Objectives
This document presents the official recommendations of the American Gastroenterological Association (AGA) on the medical management of opioid-induced constipation.
Target Patient Population
Adults with opioid-induced constipation
Inclusion Criteria
Male, Female, Adult, Older adult
Health Care Settings
Ambulatory, Hospital, Outpatient
Intended Users
Nurse, nurse practitioner, physician, physician assistant
Scope
Treatment, Management
Diseases/Conditions (MeSH)
D000079689 - Opioid-Induced Constipation
Keywords
opioids, constipation, OIC, Opioid Induced Constipation